Vogiatzi Paraskevi, Cassone Marco, Luzzi Ida, Lucchetti Chiara, Otvos Laszlo, Giordano Antonio
Sbarro Institute for Cancer Research and Molecular Medicine, Centre for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA.
J Cell Biochem. 2007 Oct 1;102(2):264-73. doi: 10.1002/jcb.21375.
The gram-negative bacterium Helicobacter pylori is known as a persistent colonizer of the human stomach, and probably less known is that it is also involved in extraintestinal diseases. Public awareness of its contribution in the development of gastric cancer is less than 15 years old. The efficacy of the current therapies based on antibiotics against H. pylori has been limited by difficulties such as antibiotic resistance and recurrence. As a consequence, the development of promising vaccines was prompted as the best preventive measure. Unfortunately, so far vaccines failed the transition from animal models to human trials. This keynote presentation is to provide a bird's eye view of H. pylori-related gastric diseases, including gastric cancer, with a synthesis of the molecular mechanisms involved, and an exhaustive presentation and discussion of the current therapeutic guidelines and future strategies for prevention or therapy.
革兰氏阴性菌幽门螺杆菌是人类胃部的一种持续性定植菌，或许鲜为人知的是，它还与肠道外疾病有关。公众对其在胃癌发生发展中的作用的认识还不到15年。目前基于抗生素治疗幽门螺杆菌的疗法效果受到诸如抗生素耐药性和复发等困难的限制。因此，开发有前景的疫苗作为最佳预防措施被提上日程。不幸的是，到目前为止，疫苗未能从动物模型过渡到人体试验。本主题演讲旨在全面介绍与幽门螺杆菌相关的胃部疾病，包括胃癌，综合阐述其中涉及的分子机制，并详尽介绍和讨论当前的治疗指南以及预防或治疗的未来策略。
